| Outcome Measures: |
Primary: AUCins.0-12h, PK endpoint: The area under the insulin concentration curve from 0 to 12 hours, 0 -12 hours|Cins.max, PK endpoint: The maximum observed insulin concentration, 0 -12 hours|AUCGIR.0-12h, PD endpoint: The area under the glucose infusion rate curve from 0 to 12 hours, 0 - 12 hours|GIRmax, PD endpoint: The maximum glucose infusion rate, 0 - 12 hours | Secondary: AUCins.0-2h, PK endpoint: The area under the insulin concentration curve from 0 to 2 hours, 0 - 2 hours|AUCins.0-∞, PK endpoint: The area under the insulin concentration-time curve from 0 hours to infinity, 0 - 12 hours|tins.max, PK endpoint: The time to maximum observed insulin concentration, Up to Day 68|t50%-ins(early), PK endpoint: The time to half-maximum insulin concentration before Cins.max, Up to Day 68|t50%-ins(late), PK endpoint: The time to half-maximum insulin concentration after Cins.max, Up to Day 68|t½, PK endpoint: The terminal serum elimination half-life calculated as t½=ln2/λz, Up to Day 68|λz, PK endpoint: The terminal elimination rate constant of insulin, Up to Day 68|AUCGIR.0-2h, PD endpoint: The area under the glucose infusion rate curve from 0 to 2 hours, 0 - 2 hours|tGIR.max, PD endpoint: The time to maximum glucose infusion rate, Up to Day 68|tGIR.50%-early, PD endpoint: The time to half-maximum glucose infusion rate before GIRmax, Up to Day 68|tGIR.50%-late, PD endpoint: The time to half-maximum glucose infusion rate after GIRmax, Up to Day 68|PD endpoint, time to onset of action, Up to Day 68|Safety and local tolerability, Number of participants experiencing treatment-emergent adverse events, Up to Day 68
|
